Free to Read
Enhanced Anti-tumor Effect of Trastuzumab in Combination with Cisplatin
Ichiro Naruse,
Hisao Fukumoto,
Nagahiro Saijo,
Kazuto Nishio,
Ichiro Naruse
Pharmacology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
First Department of Internal Medicine, Gunma University School of Medicine, 3-39-155 Showamachi, Maebashi, Gunma 371-8511
Search for more papers by this authorHisao Fukumoto
Pharmacology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
Search for more papers by this authorNagahiro Saijo
Pharmacology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
Search for more papers by this authorCorresponding Author
Kazuto Nishio
Pharmacology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
To whom correspondence should be addressed. E-mail: [email protected]Search for more papers by this authorIchiro Naruse,
Hisao Fukumoto,
Nagahiro Saijo,
Kazuto Nishio,
Ichiro Naruse
Pharmacology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
First Department of Internal Medicine, Gunma University School of Medicine, 3-39-155 Showamachi, Maebashi, Gunma 371-8511
Search for more papers by this authorHisao Fukumoto
Pharmacology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
Search for more papers by this authorNagahiro Saijo
Pharmacology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
Search for more papers by this authorCorresponding Author
Kazuto Nishio
Pharmacology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
To whom correspondence should be addressed. E-mail: [email protected]Search for more papers by this authorAbstract
The oncogenenic transmembrane tyrosine kinase receptor HER–2/neu is a promising target for treatment of HER–2–overexpressing cancers. The humanized anti-HER–2/neu antibody Trastuzumab is under clinical evaluation in combination with chemotherapy against breast cancer. The combination of Trastuzumab and cisplatin is expected to be active against HER–2/neu-expressing tumors. We examined the mechanisms of this combination effect against human solid tumor cells in the presence of human peripheral blood mononuclear cells (PBMCs) using an in vitro MTT assay. The growth-inhibitory effects of cisplatin (CDDP) on the tumor cells were not significantly affected by Trastuzumab in the absence of effector cells. CDDP alone at a dose of less than 12.5 μM did not affect the viability of PBMCs, as determined by MTT assay, suggesting that PBMCs could exert antibody-dependent cell-mediated cytotoxicity (ADCC) at this CDDP concentration. The combination of Trastuzumab and CDDP showed higher cytotoxic effects against the tumor cells in the presence of PBMCs. The CDDP concentration required to inhibit tumor cell growth by 50% was reduced to ∼20% by Trastuzumab in the presence of PBMCs at an effector/target ratio of 10. It may be important to select combined chemotherapeutic agents which do not diminish the ADCC activity of Trastuzumab via PBMCs. Both the expression of HER–2/neu and the ADCC activity may be important determinants of the therapeutic benefit of the Trastuzumab/CDDP combination.
REFERENCES
- 1 ) Coussens , L. , Yang-Feng , T. L. , Liao , Y. C. , Chen , E. , Gray , A. , McGrath , J. , Seeburg , P. H. , Libermann , T. A. , Schlessinger , J. , Francke , U. , Arthur , L. and Axel , U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene . Science , 230 , 1132 – 1139 ( 1985 ).
- 2 ) Semba , K. , Kamata , N. , Toyoshima , K. and Yamamoto , T. A v-erbB-related protooncogene, c-erbB–2, is distinct from the c-erbB–1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma . Proc. Natl. Acad. Sci. USA , 82 , 6497 – 6501 ( 1985 ).
- 3 ) Slamon , D. J. , Godolphin , W. , Jones , L. A. , Holt , J. A. , Wong , S. G. , Keith , D. E. , Levin , W. J. , Stuart , S. G. , Udove , J. , Ullrich , A. and Press , M. F. Studies of the HER–2/neu proto-oncogene in human breast and ovarian cancer . Science , 244 , 707 – 712 ( 1989 ).
- 4 ) Slamon , D. J. , Clark , G. M. , Wong , S. G. , Levin , W. J. , Ullrich , A. and McGuire , W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER–2/neu oncogene . Science , 235 , 177 – 182 ( 1987 ).
- 5 ) Seshadri , R. , Firgaira , F. A. , Horsfall , D. J. , McCaul , K. , Setlur , V. and Kitchen , P. Clinical significance of HER–2/ neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group . J. Clin. Oncol. , 11 , 1936 – 1942 ( 1993 ).
- 6 ) Press , M. F. , Bernstein , L. , Thomas , P. A. , Meisner , L. F. , Zhou , J. Y. , Ma , Y. , Hung , G. , Robinson , R. A. , Harris , C. , El-Naggar , A. , Slamon , D. J. , Phillips , R. N. , Ross , J. S. , Wolman , S. R. and Flom , K. J. HER–2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas . J. Clin. Oncol. , 15 , 2894 – 2904 ( 1997 ).
- 7 ) Hudziak , R. M. , Schlessinger , J. and Ullrich , A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells . Proc. Natl. Acad. Sci. USA , 84 , 7159 – 7163 ( 1987 ).
- 8 ) Sadasivan , R. , Morgan , R. , Jennings , S. , Austenfeld , M. , van Veldhuizen , P. , Stephens , R. and Noble , M. Overex-pression of Her–2/neu may be an indicator of poor prognosis in prostate cancer . J. Urol. , 150 , 126 – 131 ( 1993 ).
- 9 ) Myers , R. B. , Oelschlager , D. K. , Hockett , R. D. , Rogers , M. D. , Conway-Myers , B. A. and Grizzle , W. E. The effects of dihydrotestosterone on the expression of p185 (erbB–2) and c-erbB–2 mRNA in the prostatic cell line LNCaP . J. Steroid Biochem. Mol. Biol. , 59 , 441 – 447 ( 1996 ).
- 10
)
Myers , R. B.
,
Brown , D.
,
Oelschlager , D. K.
,
Waterbor , J. W.
,
Marshall , M. E.
,
Srivastava , S.
,
Stockard , C. R.
,
Urban , D. A.
and
Grizzle , W. E.
Elevated serum levels of p105 (erbB–2) in patients with advanced-stage prostatic adenocarcinoma
.
Int. J. Cancer
,
69
,
398
–
402
(
1996
).
10.1002/(SICI)1097-0215(19961021)69:5<398::AID-IJC8>3.0.CO;2-0 CAS PubMed Web of Science® Google Scholar
- 11 ) Drebin , J. A. , Link , V. C. , Stern , D. F. , Weinberg , R. A. and Greene , M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies . Cell , 41 , 697 – 706 ( 1985 ).
- 12 ) Sasaki , S. , Tsujisaki , M. , Jinnohara , T. , Ishida , T. , Sekiya , M. , Adachi , M. , Takahashi , S. , Hinoda , Y. and Imai , K. Human tumor growth suppression by apoptosis induced with anti-ErbB–2 chimeric monoclonal antibody . Jpn. J. Cancer Res. , 89 , 562 – 570 ( 1998 ).
- 13 ) Hudziak , R. M. , Lewis , G. D. , Winget , M. , Fendly , B. M. , Shepard , H. M. and Ullrich , A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor . Mol. Cell. Biol. , 9 , 1165 – 1172 ( 1989 ).
- 14 ) Fendly , B. M. , Winget , M. , Hudziak , R. M. , Lipari , M. T. , Napier , M. A. and Ullrich , A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product . Cancer Res. , 50 , 1550 – 1558 ( 1990 ).
- 15
)
Brodowicz , T.
,
Wiltschke , C.
,
Budinsky , A. C.
,
Krainer , M.
,
Steger , G. G.
and
Zielinski , C. C.
Soluble HER–2/neu neutralizes biologic effects of anti-HER–2/neu antibody on breast cancer cells in vitro
.
Int. J. Cancer
,
73
,
875
–
879
(
1997
).
10.1002/(SICI)1097-0215(19971210)73:6<875::AID-IJC19>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 16 ) Sliwkowski , M. X. , Lofgren , J. A. , Lewis , G. D. , Hotaling , T. E. , Fendly , B. M. and Fox , J. A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) . Semin. Oncol. , 26 , 60 – 70 ( 1999 ).
- 17 ) Osoba , D. and Burchmore , M. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin) . Semin. Oncol. , 26 , 84 – 88 ( 1999 ).
- 18 ) Shak , S. Overview of the trastuzumab (Herceptin) anti HER2 monoclonal antibody clinical program in HER2–overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group . Semin. Oncol. , 26 , 71 – 77 ( 1999 ).
- 19 ) Weiner , L. M. An overview of monoclonal antibody therapy of cancer . Semin. Oncol. , 26 , 41 – 50 ( 1999 ).
- 20 ) Baselga , J. , Tripathy , D. , Mendelsohn , J. , Baughman , S. , Benz , C. C. , Dantis , L. , Sklarin , N. T. , Seidman , A. D. , Hudis , C. A. , Moore , J. , Rosen , P. P. , Twaddell , T. , Henderson , I. C. and Norton , L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer . J. Clin. Oncol. , 14 , 737 – 744 ( 1996 ).
- 21 ) Baselga , J. , Norton , L. , Albanell , J. , Kim , Y. M. and Mendelsohn , J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts . Cancer Res. , 58 , 2825 – 2831 ( 1998 ).
- 22 ) Hortobagyi , G. N. Recent progress in the clinical development of docetaxel (Taxotere) . Semin. Oncol. , 26 , 32 – 36 ( 1999 ).
- 23 ) Yen , L. , Nie , Z. R. , You , X. L. , Richard , S. , Langton-Webster , B. C. and Alaoui-Jamali , M. A. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185 (erbB–2) is dependent on the ras signaling pathway . Oncogene , 14 , 1827 – 1835 ( 1997 ).
- 24 ) Hancock , M. C. , Langton , B. C. , Chan , T. , Toy , P. , Monahan , J. J. , Mischak , R. P. and Shawver , L. K. A monoclonal antibody against the c-erbB–2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines . Cancer Res. , 51 , 4575 – 4580 ( 1991 ).
- 25 ) Langton-Webster , B. C. , Xuan , J. A. , Brink , J. R. and Salomon , D. S. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB–2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line . Cell Growth Differ. , 5 , 1367 – 1372 ( 1994 ).
- 26 ) Arteaga , C. L. , Winnier , A. R. , Poirier , M. C. , Lopez-Larraza , D. M. , Shawver , L. K. , Hurd , S. D. and Stewart , S. J. p185c-erbB–2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair . Cancer Res. , 54 , 3758 – 3765 ( 1994 ).
- 27 ) Pegram , M. D. and Slamon , D. J. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptorenhanced chemosensitivity . Semin. Oncol. , 26 , 89 – 95 ( 1999 ).
- 28
)
Fukumoto , H.
,
Nishio , K.
,
Ohta , S.
,
Hanai , N.
and
Saijo , N.
Reversal of adriamycin resistance with chimeric anti-ganglioside GM2 antibody
.
Int. J. Cancer
,
67
,
676
–
680
(
1996
).
10.1002/(SICI)1097-0215(19960904)67:5<676::AID-IJC14>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 29 ) Mosmann , T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays . J. Immunol. Methods , 65 , 55 – 63 ( 1983 ).
- 30 ) Sung , M. W. , Nagashima , S. , Johnson , J. T. , van Dongen , G. A. and Whiteside , T. L. The role of apoptosis in antibody-dependent cell-mediated cytotoxicity against monolayers of human squamous cell carcinoma of the head and neck targets . Cell. Immunol. , 171 , 20 – 29 ( 1996 ).
- 31 ) Bhat , N. M. , Bieber , M. M. , Stevenson , F. K. and Teng , N. N. Rapid cytotoxicity of human B lymphocytes induced by VH4–34 (VH4.21) gene-encoded monoclonal antibodies . Clin. Exp. Immunol. , 105 , 183 – 190 ( 1996 ).
- 32 ) Fujieda , M. , Oishi , N. and Kurashige , T. Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment . Clin. Exp. Immunol. , 107 , 120 – 126 ( 1997 ).
- 33
)
Kanzawa , F.
,
Nishio , K.
,
Fukuoka , K.
,
Fukuda , M.
,
Kunimoto , T.
and
Saijo , N.
Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC–3
.
Int. J. Cancer
,
71
,
311
–
319
(
1997
).
10.1002/(SICI)1097-0215(19970502)71:3<311::AID-IJC1>3.0.CO;2-0 CAS PubMed Web of Science® Google Scholar
- 34 ) Fukuda , M. , Nishio , K. , Kanzawa , F. , Ogasawara , H. , Ishida , T. , Arioka , H. , Bojanowski , K. , Oka , M. and Saijo , N. Synergism between cisplatin and topoisomerase I inhibitors, NB–506 and SN–38, in human small cell lung cancer cells . Cancer Res. , 56 , 789 – 793 ( 1996 ).
- 35
)
Fukumoto , H.
,
Nishio , K.
,
Ohta , S.
,
Hanai , N.
,
Fukuoka , K.
,
Ohe , Y.
,
Sugihara , K.
,
Kodama , T.
and
Saijo , N.
Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2–expressing solid tumors in vivo
.
Int. J. Cancer
,
82
,
759
–
764
(
1999
).
10.1002/(SICI)1097-0215(19990827)82:5<759::AID-IJC22>3.0.CO;2-H CAS PubMed Web of Science® Google Scholar
- 36 ) Pietras , R. J. , Fendly , B. M. , Chazin , V. R. , Pegram , M. D. , Howell , S. B. and Slamon , D. J. Antibody to HER–2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells . Oncogene , 9 , 1829 – 1838 ( 1994 ).
- 37 ) Martin , M. , Diaz-Rubio , E. , Casado , A. , Santabarbara , P. , Lopez Vega , J. M. , Adrover , E. and Lenaz , L. Carboplatin: an active drug in metastatic breast cancer . J. Clin. Oncol. , 10 , 433 – 437 ( 1992 ).
- 38 ) McClay , E. F. and Howell , S. B. A review: intraperitoneal cisplatin in the management of patients with ovarian cancer . Gynecol. Oncol. , 36 , 1 – 6 ( 1990 ).
